 |
Expert Opinions
Expert Opinions
“Dr. Adler has an impeccable scientific reputation and is regarded as a leader in the field of lung biology research. His novel finding that inhibition of the MARCKS-related peptide blocked mucus secretion and improved lung function in a mouse model of mucus hypersecretion was published in Nature Medicine, our most prestigious publication of this sort. The clinical potential of this finding is huge, since there is very little that we do for COPD patients that control mucus secretion or effects disease outcome. I am very pleased to see Dr. Adler and his able group focusing on a novel COPD therapy – the medical community greatly needs this.”
 |
Steven
D. Shapiro, M.D. Professor and Chair University of Pittsburgh School of Medicine |
“It is well known that Chronic Obstructive Pulmonary Disease (COPD) is a devastating illness and the 4th leading cause of death in the US. It is projected to become the 3rd leading cause in 5 years which points out the need to develop novel and more effective therapies for this debilitating disease. Dr. Adler’s discovery has significant clinical implications and the potential of this finding is very important, since there is not much in the armamentarium of a clinician to treat COPD patients to control mucus secretion which is a major contributor to the morbidity of these patients. As such, I am pleased to learn that the research group led by Dr. Adler is focusing on this novel COPD therapeutic strategy which has the potential to improve morbidity and mortality of this patient population.”
 |
Jacob
I. Sznajder, M.D. Professor of Medicine and Chief Northwestern University Feinberg School of Medicine Division of Pulmonary and Critical Care Medicine |
“The clinical implication of this work is the real hope of generating new therapeutic targets to limit or regulate abnormal mucus hypersecretion. At this time, there are no effective therapies that effectively block mucus secretion in this and other pulmonary diseases, and current pharmacological treatments can induce only slight improvements in COPD patients. The peptides that Dr. Adler discovered and described in the articles his laboratory published in the prestigious journals, Nature Medicine and The Journal of Biological Chemistry, and recently shown to enhance lung function in a mouse model of mucus hypersecretion raise the strong possibility that new and effective therapies based on his discovery of new cellular targets associated with these diseases can be developed.”
 |
Joseph
G. N. Garcia, M.D. Professor of Medicine and Chairman, Department of Medicine The University of Chicago Pritzker School of Medicine |
“Dr. Adler has been a leader in research in airway biology for decades. His contributions are widely recognized and have had major impacts on his fields. Airway biology is currently one of the most important areas of lung research, and his recent studies are extremely significant. I have long thought that numerous patients could benefit from his discovery of MARCKS protein's role in airway inflammation and mucus secretion. All the recent advances n Dr. Adler's study of this protein and his work with BioMarck increase my expectations for successful therapeutic application.”
 |
Edward
Crandall, Ph.D., M.D. Chair, Department of Medicine University of Southern California Keck School of Medicine |
“These findings have the potential to significantly impact a very difficult problem in clinical medicine. Patients with airway diseases such as asthma and COPD are greatly compromised by obstruction of their pulmonary airways with mucus. Moreover, there are no effective and specific therapies for this common problem at present. Thus, a specific means for preventing or reversing mucus obstruction would represent a major breakthrough in the treatment of chronic obstructive lung disease.”
 |
Michael
J. Holtzman, M.D. Professor and Director Washington University School of Medicine Pulmonary and Critical Care Medicine |
“Increased mucous secretion presents a severe problem for patients with a number of pulmonary disorders including, but not limited to, COPD, asthma and cystic fibrosis. The lack of effective therapies for mucous hypersecretion compels examination of alternative pathways. As demonstrated by Dr. Adler’s publications in the most prestigious journals (Nature Medicine, JBC, and JAP), the peptides that Dr. Adler describes are shown to effectively improve pulmonary functions in models of mucous hypersecretion. Thus, Dr. Adler has the potential to greatly influence the care and clinical course of a number of debilitating pulmonary diseases.”
 |
Patricia
W. Finn, M.D. Professor of Medicine Director, Pulmonary and Critical Care Medicine University of California, San Diego School of Medicine |
"Dr. Adler was the first to recognize that MARCKS protein controls the release of mucus from airway epithelial cells. This highly innovative research provides the first truly novel approach to treatment of COPD, as well as other lung diseases characterized by mucus hypersecretion, since I have been involved in lung research. It would be difficult to overemphasize the importance of this research, and of the necessity to move this into human subjects and patients as quickly as possible. This new approach has the potential to improve the health and quality of life for millions of patients with COPD and other lung diseases."
 |
David
B. Jacoby, M.D. Professor of Medicine, Physiology and Pharmacology, and Anesthesiology and Peri-Operative Medicine Edwards Professor of Pulmonary Medicine Deputy Director, Oregon Clinical and Translational Research Institute. Chief, Pulmonary and Critical Care |
|
|
© Copyright 2008 BioMarck Pharmaceuticals. All
Rights Reserved.